Generex Biotechnology Corp (GNBT)

GNBT's Oral insulin delivery system is a significant advancement in the treatment of Diabetes Mellitus and will be soon approved for use in the USA. It will be a cash cow, funding the companies cancer treatment programs for the foreseeable future.

I expect GNBT to be a blockbuster stock.

jpg101 @5.53

Good potential. desired remedy. easy medication control for diabetes & others.

GNBT is one of the few companies that is making insulin that is deliverable by the oral route, the advantages of generex's product is that it's delivered via the mucous membrane of the mouth,rather then inhaled and absorbed by the lung as other oral insulin makers, the latter deliver method has a number of disadvantages including variable absorption and problems in patients with lung disease.
generex also holds a number of patents based on antigen treatment via mucous membrane absorption to treat a variety of infectious or carcinomatous diseases- these are in the development phase, if successful the company would have significant gains.
this companies insulin product hasn't been approved in the US yet- it has been approved in ecuador and recently in india-

I have owned stock in the company for about a year now and have watched it rise big and then fall big. They have a new delivery method for drugs through an inhaler that I think will be a big hit though.

Stock has gained first large country approval (India) for Oralynn and should gain approvals in Canada and then USA not long after.Wall Street has just begun to notice this company with three firms setting price targets ranging from $5.50 to $7.00.Not bad for a stock currently trading under $2.00 to be recieved that way on Wall Street.

biotech

Rates of diabetes will continue to climb. This company is developing a spray insulin delivery system. After they get FDA approval in the US, this stock should go up.

Ora-Lyn will come to market

Oral insulin.

Definitley a up and comer with Phase III trials beginning soon, several pipeline revenue streams currently active in third world countries and the cancer/avian bird flu vaccine work, they are also a likely target for takeover by a big firm.

Will concede the point on trying to bypass FDA testing reg's though, I've heard that about them in the past, hopefully Phase III will put that issue to rest as this company could easily be a groundbreaker.

is this up an coming

Still a very small developmental drug company. Has now moved into Phase III trials and if approved, revenues could drive stock price high.

interesting pipeline

their oral diabetes drug could be big

Hey, I;m out with my family or friends, and I need to stick a needle in my arm to get my insulin or turn my head, and breath my asthma pump like spray. This is a no brainer. This will go with world wide appeal, and grow like a supernova. BUY. BUY. BUY. and when your done buy some more.

the molecular process works, now they need to stick something in the machine and sell it. When they start getting revenue, this one will explode.

Okay. R&R just put out a 6 PT on this. If you like this company, you will really like micro-cap, NVD, with a much broader patent protection on its oral spray technology. Rumors have NVD working with Phizer on oral viagra. They have NDA filing for Zolpidem which should get a partnership this year.

Okay. Please excuse the shameless NVD pump. I just think its greatly undervalued considering this company is worth twice as much.

Spec. Bio-tech stock. Risky, but hey thats what makes investing fun!!